Study for using sulfate in the prevention and control of novel coronavirus pneumonia (COVID-19) in high and low prevalence communities

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000032487

Enrollment

Unknown

Registered

2020-04-29

Start date

2020-03-26

Completion date

Unknown

Last updated

2020-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Interventions

Experimental group:Administration of hydroxychloroquine sulfate

control group:Placebo given

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Healthy subjects with negative covid-19 nucleic acid test and antibody test; 2. Aged 18-70 years old; 3. Signed informed consent and participated in the study voluntarily.

Exclusion criteria

Exclusion criteria: 1. Patients allergic to chloroquine and hydroxychloroquine; 2. Pregnant women; 3. Patients with severe diseases of heart, lung, kidney, brain, blood and other important organs and dysfunction; 4. Patients with retinopathy, hearing loss or hearing loss; 5. Patients with severe neurological and psychiatric diseases; 6. Subjects who, in the opinion of the investigator, were unable to complete the study as required or were not suitable to participate in the study.

Design outcomes

Primary

Measure	Time frame
Detection of nucleic acid and antibody of new coronavirus ;	—

Countries

China

Contacts

Public ContactShuihua Lu

Shanghai Public Health Clinical Center

lushuihua@shphc.org.cn+86 18930811818

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026